EntreMed begins phase 1 trial of ENMD-1198 in advanced cancer

By Lisa Kerner

Erie, Pa., May 2 - EntreMed, Inc. said it began a phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics and clinical benefit of its novel tubulin binding agent, ENMD-1198, in patients with advanced cancer.

The single-center, dose-escalation study will be conducted at the University of Colorado at Denver and Health Sciences Center in Aurora, Colo., on patients whose advanced cancer has failed to respond to existing therapies or where no approved therapy is available.

ENMD-1198, a new chemical entity, is designed to decrease metabolism while inducing apoptosis, binding microtubules, and inhibiting HIF-1alpha, according to a company news release.

"Results from preclinical studies with this compound highlight its significant antitumor activity and multiple mechanisms of action, including inhibiting three transcription factors, HIF-1alpha, NF-kappaB and Stat3, known to promote tumorigenesis," vice president and chief medical officer Carolyn F. Sidor said in the news release.

"With the initiation of this study, EntreMed now has three product candidates, Panzem NCD, MKC-1 and ENMD-1198, in clinical trials for cancer patients, with additional trials planned for later this year."

EntreMed is a Rockville, Md., clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.